US-based pharmaceutical company Bristol Myers Squibb has brought 12 innovations in the areas of oncology, haematology, and immunology to the ongoing 5th China international Import Expo and will continue to help patients with unmet needs in China by introducing up to 30 innovative medicines or indications by 2025, said its China president.

"The 5th CIIE fully demonstrates China's firm determination to further open up and share market opportunities with the world," said Chen Siyuan, president and general manager of BMS China.

"It also brings strong confidence to multinational enterprises like Bristol Myers Squibb, which will continue to contribute to China's economic development. The act of increasing imports fully showcases China's responsibilities as a major country and reflects its commitment to building a community with a shared future for mankind."

China is now the second largest pharmaceutical market in the world and has been making efforts, including increasing patient needs and expanding healthcare infrastructure and regulatory and reimbursement reforms, that open the door for innovative medicines to reach more patients who urgently need them, Chen added.

As such, Bristol Myer Squibb, the first Sino-US pharmaceutical joint venture following China's move to enact reform and opening-up, will ride the current momentum and continue to drive innovation and increase investments in the country over the next 10 years, Chen said.

The company is planning to bring up to 30 innovative medicines or indications to China by 2025 and will be keenly involved in global early development programs to achieve simultaneous development in the areas of high unmet needs in China.

"We are also advancing our commitment to broadening patient access in the multi-layer medical security system of China and striving to become a trusted partner in the healthcare ecosystem in China," she said.